

Supplementary Information File:

A machine-learning approach to human ex vivo lung perfusion predicts transplantation outcomes and promotes organ utilization

Table of Contents:

Supplementary Figures.....Page 2

Figure 1: In sighTx model performance on test data

Figure 2: Net Benefit of the In sighTx model

Supplementary Tables.....Page 4

Table 1: Performance (AUROC) of donor and/or recipient models that predict time to extubation in transplanted patients

Table 2: Recipient and donor characteristics for In sighTx model assessment

Table 3: Summary of the theoretical impact of In sighTx on organ utilization and impression


Table 4: Summary of the theoretical transplantation rates by EVLP experience with and without In sighTx

Table 5: Summary of source data acquisition for the In sighTx model

Table 6: All EVLP features used in the In sighTx model


Table 7: Summary of quantitative data derived from EVLP assessment features

Table 8: Transplant patient characteristics for In sighTx with recipient features model




Supplementary Figure 1: InsignTx model performance on test data. AUROC graphs for the InsignTx model performance in Test Dataset 1 (a) and Test Dataset 2 (b). Shown are the AUROCs for the overall model (dotted blue line), prediction of post-transplant extubation <72h (black line), ≥72h (blue line), and unsuitable for transplant (yellow line). The dashed line represents an AUROC of 50%. Panel (c) and (d) show the AUPRC graphs for the InsignTx model performance in Test Dataset 1 and Test Dataset 2, respectively. Shown are the AUPRCs for the prediction of post-transplant extubation <72h (black line), ≥72h (blue line), and unsuitable for transplant (yellow line). The dashed lines represent the baseline AUPRC for each outcome. Bootstrapped AUROC and AUPRC values are reported in the respective figure legends. Source data are provided as a Source Data file.

a.



b.



Supplementary Figure 2: Net Benefit of the InsighTx model. Net benefit graphs of the InsighTx model (blue trace) compared to transplant 'all' (red trace) or 'none' (green trace) approaches to predict transplant suitability (a) or post-transplant extubation <72h (b). Source data are provided as a Source Data file.

Supplementary Table 1: Performance (AUROC) of donor and/or recipient models that predict time to extubation in transplanted patients

Model	AUROC (SD)
<i>InsignTx + Recipient Features</i>	79 (4)
<i>InsignTx</i>	73 (8)
<i>Recipient Features Only</i>	69 (6)
<i>p-value</i> ¹	0.17
<i>p-value</i> ²	0.01

Legend: 1: p-value for “InsignTx + Recipient Features” vs. “InsignTx”; 2: p-value for “InsignTx + Recipient Features” vs. “Recipient Features”; AUROC=area under receiver operating characteristic curve (%); SD=standard deviation. A detailed description of the p-value calculations can be found in the Methods.

Supplementary Table 2: Recipient and donor characteristics for InsignTx model assessment

	Study Cases
Date Range	2008-2020
Number of Cases	20
Mean Age (SD) – Years	
<i>Donor</i>	45 (16)
<i>Recipient</i>	57 (12)
Male Sex (%)	
<i>Donor</i>	13 (65%)
<i>Recipient</i>	12 (60%)
Donor Type DBD (%)	10 (50%)
Recipient Status (%)	
1	6 (30%)
2	10 (50%)
3	4 (20%)
Recipient Disease (%)	
<i>Emphysema/COPD</i>	6 (30%)
<i>Cystic Fibrosis</i>	2 (10%)
<i>PF/ILD/UIP/NSIP</i>	10 (50%)
<i>Other</i>	2 (10%)
EVLP Outcome	
<i>Transplanted (%)</i>	8 (40%)
<i>Declined (%)</i>	12 (60%)
Transplant Outcome	
<i>Extubated <72h (%)</i>	3 (38%)
<i>PGD 3 at 72h (%)</i>	2 (25%)
<i>ICU LOS [IQR] - Days</i>	5 [3-7]

Legend: SD=standard deviation; DBD=donation after brain death; EVLP=ex vivo lung perfusion; PGD=primary graft dysfunction; ICU=intensive care unit; LOS=length of stay; IQR=interquartile range; PF=pulmonary fibrosis; ILD=interstitial lung disease; UIP=usual interstitial pneumonia; NSIP=nonspecific interstitial pneumonia; COPD=chronic obstructive pulmonary disease.

Supplementary Table 3: Summary of the theoretical impact of InsignTx on organ utilization and impression

Historical Outcome	Predicted Outcome	No. Decisions	InsignTx vs. SOC	
			ΔTransplant Decisions	ΔClinical Impression of Donor Lung†
<i>Extubated <72h Post-Transplant</i>	<i>Extubated <72h Post-Transplant</i>	45	+7% (+3 decisions to Tx)	+1.0
<i>Unsuitable for Transplant</i>	<i>Unsuitable for Transplant</i>	45	-4% (-2 decisions to Tx)	-1.0
<i>Extubated ≥72h Post-Transplant</i>	<i>Extubated ≥72h Post-Transplant</i>	75	-13% (-10 decisions to Tx)	0
<i>Unsuitable for Transplant</i>	<i>Extubated <72h Post-Transplant</i>	135	+13% (+18 decisions to Tx)	+0.5

† Assessors were asked to rank the overall impression of a donor lung from poor (0) to excellent (10). Shown are the changes in clinical impression for suitable and unsuitable donor lungs when the InsignTx model was available. Legend: SOC=standard of care; EVLP=ex vivo lung perfusion.

Supplementary Table 4: Summary of the theoretical transplantation rates (%) by EVLP experience† with (+) and without (-) InsignTx

EVLP Experience	Unsuitable Donor Lungs		Suitable Donor Lungs	
	- InsignTx	+ InsignTx	- InsignTx	+ InsignTx
100+	74%	66%	54%	70%
<100	55%	38%	43%	54%

† : experience defined as the number of clinical EVLP cases performed by the assessor – a threshold of 100 cases was used.

Supplementary Table 5: Summary of source data acquisition for the InsignTx model

Input Feature	Data Source	Data Recording	Acquisition Time	Data Notes
Donor characteristics	Patient charts	Text	Instantaneous	N/A
Physiological (i.e., compliance, airway pressure)	ICU grade ventilator (i.e., Maquet Servo-i or similar)	Continuous monitoring	Instantaneous	Recorded hourly
Physiological (i.e., PA and LA pressure)	Pressure monitor (i.e., Philips IntelliVue MX450)	Continuous monitoring	Instantaneous	Recorded hourly
Physiological (i.e., gas exchange)	Perfusate sampling and ABG analysis (i.e., Siemens Rapid-point or similar)	As samples are drawn	<5 minutes	Samples drawn during hourly assessment or as needed
Biochemical (i.e., acid base chemistry, electrolytes)	Perfusate sampling and ABG analysis (i.e., Siemens Rapid-point or similar)	As samples are drawn	<5 minutes	Samples drawn during hourly assessment or as needed
Biological (i.e., cytokines)	Perfusate sampling and ELISA-based analysis (i.e., SQI TORdx LUNG or similar)	Batched sampling during EVLP	<40 minutes	Samples drawn during EVLP to capture cytokine profile
Edema (i.e., perfusate loss and volume exchanges)	Perfusate reservoir	Manual recording	Instantaneous	Annotated hourly by Organ Perfusion Specialists

Legend: LA=left atrial; PA=pulmonary artery; ABG=arterial blood gas

Supplementary Table 6: All EVLP features used in the InsignTx model

Donor	Physiological	Biochemical	Biological
Age	ΔpO_2	Ca^{2+}	IL-10
Sex	ΔpCO_2	Cl^-	IL-1 β
BMI	Dynamic Compliance	K^+	IL-6
Donor Type (DBD vs DCD)	Static Compliance	Na^+	IL-8
	PA & LA Pressure	Base Excess	
	Vascular Resistance	HCO_3^-	
	Airway Pressure (Peak, Mean, Plateau)	pH	
	PEEP	Glucose	
	Volume of perfusate loss and exchange	Lactate	

Legend: ΔpO_2 =change in oxygen partial pressure; ΔpCO_2 =change in carbon dioxide partial pressure; LA=left atrial; PA=pulmonary artery; IL-8=interleukin-8; IL-6=interleukin-6; IL-10=interleukin-10; IL-1 β =interleukin-1beta; BMI=body mass index; DBD=donation after brain death; DCD=donation after cardiac death; PEEP=positive end-expiratory pressure.

Supplementary Table 7: Summary of quantitative data derived from EVLP assessment features†

Parameter	N Data Points	Median [IQR]
Physiological		
ΔpO_2 (mmHg)	2,720	437 [377 – 485]
ΔpCO_2 (mmHg)	2,442	-6 [(-7) – (-4)]
Dynamic Compliance (mL/cmH ₂ O)	2,654	73 [53 – 89]
Static Compliance (mL/cmH ₂ O)	2,604	114 [82 – 147]
LA Pressure (mmHg)	6,010	4 [4 – 5]
PA Pressure (mmHg)	6,011	7 [6 – 8]
Pulmonary Vascular Resistance (dynes/sec/cm ⁵)	5,654	175 [103 – 296]
Peak Pressure (cmH ₂ O)	5,354	13 [12 – 15]
Plateau Pressure (cmH ₂ O)	2,655	11 [10 – 13]
Mean Pressure (cmH ₂ O)	5,327	7 [7 – 8]
PEEP (cmH ₂ O)	6,733	5 [5 – 5]
Perfusate addition (mL)	2,601	250 [250 – 500]
Perfusate removal (mL)	1,795	250 [125 – 250]
Edema (perfusate loss) (mL)	1,481	90 [50 – 175]
Biochemical		
Ca ²⁺ (mmol/L)	2,474	0.87 [0.84 – 0.91]
Cl ⁻ (mmol/L)	2,610	125 [123 – 127]
K ⁺ (mmol/L)	2,685	4.3 [4.1 – 4.6]
Na ⁺ (mmol/L)	2,585	150 [148 – 153]
Base Excess (mmol/L)	2,638	-24 [(-27) – (-21)]
HCO ₃ ⁻ (mmol/L)	2,632	5.9 [4.3 – 7.6]
pH	2,444	7.08 [6.95 – 7.19]
Glucose (mmol/L)	3,639	7.5 [6.0 – 8.6]
Lactate (mmol/L)	2,186	5.8 [3.8 – 8.3]
Biological		
IL-6 (pg/mL)	1,261	4,758 [707 – 18,850]
IL-8 (pg/mL)	1,259	467 [119 – 2,932]
IL-1 β (pg/mL)	766	5.4 [1.7 – 15.0]
IL-10 (pg/mL)	756	76.1 [12.8 – 172.8]

Legend: †: median proportion of cases with a missing parameter was 15%; ΔpO_2 =change in oxygen partial pressure; ΔpCO_2 =change in carbon dioxide partial pressure; LA=left atrial; PA=pulmonary artery; IL-8=interleukin-8; IL-6=interleukin-6; IL-10=interleukin-10; IL-1 β =interleukin-1beta; PEEP=positive end-expiratory pressure.

Supplementary Table 8: Transplant patient characteristics for InsignTx with recipient features model

Number of Cases	368
Mean Age (SD) – Years	55 (14)
Sex (%)	
Female	135 (37%)
Male	233 (63%)
Mean BMI (SD)	24 (5)
Status at Assessment (%)	
1	197 (53%)
2	131 (36%)
3	40 (11%)
Status at Listing (%)	
1	197 (53%)
2	130 (36%)
3	41 (11%)
Status at Admission (%)	
1	116 (32%)
2	139 (37%)
3	113 (31%)
Indication for Transplant (%)	
<i>PF/ILD/UIP/NSIP</i>	161 (44%)
<i>Emphysema/COPD</i>	131 (36%)
<i>Cystic Fibrosis</i>	43 (12%)
<i>Primary pulmonary hypertension</i>	15 (4%)
<i>Retransplant</i>	16 (4%)
<i>Other</i>	2 (<1%)

Legend: SD=standard deviation; BMI=body mass index; PF=pulmonary fibrosis; ILD=interstitial lung disease; UIP=usual interstitial pneumonia; NSIP=nonspecific interstitial pneumonia; COPD=chronic obstructive pulmonary disease.